[go: up one dir, main page]

MX2024003619A - Metodo para producir celulas t. - Google Patents

Metodo para producir celulas t.

Info

Publication number
MX2024003619A
MX2024003619A MX2024003619A MX2024003619A MX2024003619A MX 2024003619 A MX2024003619 A MX 2024003619A MX 2024003619 A MX2024003619 A MX 2024003619A MX 2024003619 A MX2024003619 A MX 2024003619A MX 2024003619 A MX2024003619 A MX 2024003619A
Authority
MX
Mexico
Prior art keywords
cells
regulatory
producing
differentiating
disclosed
Prior art date
Application number
MX2024003619A
Other languages
English (en)
Inventor
Takayuki Sato
Shin Kaneko
Shoichi Iriguchi
Yoshiaki Kassai
Keiko Sekiya
Atsushi Matsuda
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of MX2024003619A publication Critical patent/MX2024003619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Se divulga un método para producir células T reguladoras que comprende la siguiente etapa: (1) Diferenciar células que se pueden diferenciar en células T reguladoras, a las que se introduce un constructo de expresión, en células T reguladoras; el constructo de expresión comprende: (a) Secuencia no codificante conservada (CNS) 1, CNS2, y CNS3 del gen Foxp3; (b) Un promotor; y (c) Un ácido nucleico que codifica FOXP3. También se divulgan células T reguladoras obtenidas según el método, y una composición farmacéutica que comprende las células T reguladoras.
MX2024003619A 2021-09-27 2022-09-26 Metodo para producir celulas t. MX2024003619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021157187 2021-09-27
PCT/JP2022/035626 WO2023048275A1 (ja) 2021-09-27 2022-09-26 Ｔ細胞の製造方法

Publications (1)

Publication Number Publication Date
MX2024003619A true MX2024003619A (es) 2024-04-19

Family

ID=85720842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003619A MX2024003619A (es) 2021-09-27 2022-09-26 Metodo para producir celulas t.

Country Status (12)

Country Link
US (1) US20240400993A1 (es)
EP (1) EP4410965A4 (es)
JP (1) JPWO2023048275A1 (es)
KR (1) KR20240067089A (es)
CN (1) CN118056007A (es)
AR (1) AR127141A1 (es)
AU (1) AU2022349176A1 (es)
CA (1) CA3234008A1 (es)
CO (1) CO2024004812A2 (es)
MX (1) MX2024003619A (es)
TW (1) TW202330910A (es)
WO (1) WO2023048275A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240100489A (ko) * 2021-09-08 2024-07-01 오차드 테라퓨틱스 (유럽) 리미티드 자가면역질환을 치료 또는 예방하기 위한 조성물 및 방법
JPWO2023182328A1 (es) * 2022-03-23 2023-09-28
CN120112629A (zh) * 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
CN116640728B (zh) * 2023-07-24 2023-10-20 呈诺再生医学科技(北京)有限公司 RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE502004001104D1 (de) 2004-04-10 2006-09-14 Henkel Kgaa Lockenwickler
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JP5098028B2 (ja) 2005-12-13 2012-12-12 国立大学法人京都大学 核初期化因子
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
EP2164951A2 (en) 2007-05-30 2010-03-24 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP2009237558A (ja) 2008-03-05 2009-10-15 Semiconductor Energy Lab Co Ltd 半導体装置の駆動方法
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2797598A4 (en) 2011-09-13 2015-08-12 Igor Roninson TREATMENT OF DISEASES OR DISORDERS BY INDUCED NFKB TRANSCRIPTIONAL ACTIVITY
CN104363913B (zh) 2012-02-02 2018-08-21 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
MX2015002310A (es) 2012-08-23 2015-06-05 Hoffmann La Roche Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
CN104755477B (zh) 2012-10-08 2017-09-26 默克专利股份公司 2‑氨基吡啶化合物
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
BR112015008037A2 (pt) 2012-12-10 2017-07-04 Hoffmann La Roche compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014180943A1 (en) * 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
WO2014194201A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
AR097894A1 (es) 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
EP3505521A1 (en) 2013-12-24 2019-07-03 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
CN106458992B (zh) 2014-03-27 2019-03-15 默克专利股份公司 吡啶基哌啶
JP6529085B2 (ja) 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
JP6521387B2 (ja) 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
EP3169678A1 (en) 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
JP6983771B2 (ja) * 2015-10-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
CN109415699B (zh) 2016-06-23 2024-08-27 国立大学法人京都大学 Cd4cd8双阳性t细胞的制备方法
EP3494209A1 (en) * 2016-08-05 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Ex vivo generation of mhcii restricted cd4+foxp3+ regulatory t cells and therapeutic uses thereof
WO2018135646A1 (ja) 2017-01-20 2018-07-26 国立大学法人京都大学 ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
US20190390169A1 (en) 2017-03-03 2019-12-26 Kyoto University Pancreatic progenitor cell production method
JP2020525010A (ja) * 2017-06-22 2020-08-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 制御性免疫細胞を産生するための方法及びその使用
US12060566B2 (en) * 2017-08-22 2024-08-13 The Regents Of The University Of California Self-inactivating lentiviral vector comprising a FOXP3 expression cassette
US12077774B2 (en) * 2018-04-18 2024-09-03 UCL Business Ltd. Method for enhancing the suppressive properties of Treg cells
CN119709615A (zh) 2018-08-10 2025-03-28 国立大学法人京都大学 Cd3阳性细胞的制造方法
WO2020040198A1 (ja) * 2018-08-22 2020-02-27 国立大学法人大阪大学 制御性ｔ細胞の作製法
JP2023501388A (ja) 2019-11-08 2023-01-18 サンガモ セラピューティクス， インコーポレイテッド 操作された制御性ｔ細胞の生成
EP4474476A4 (en) * 2022-02-04 2026-02-18 Univ Kyoto T-LYMPHOCYTE PRODUCTION PROCESS
JPWO2023182328A1 (es) * 2022-03-23 2023-09-28

Also Published As

Publication number Publication date
KR20240067089A (ko) 2024-05-16
TW202330910A (zh) 2023-08-01
US20240400993A1 (en) 2024-12-05
AU2022349176A1 (en) 2024-04-11
EP4410965A4 (en) 2025-09-24
CA3234008A1 (en) 2023-03-30
AR127141A1 (es) 2023-12-20
JPWO2023048275A1 (es) 2023-03-30
CN118056007A (zh) 2024-05-17
EP4410965A1 (en) 2024-08-07
WO2023048275A1 (ja) 2023-03-30
CO2024004812A2 (es) 2024-05-20

Similar Documents

Publication Publication Date Title
MX2024003619A (es) Metodo para producir celulas t.
CO2022014527A2 (es) Método y fármaco para tratar el síndrome de hurler
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
MX2021011031A (es) Proceso de transcripción in vitro en lotes alimentados.
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
BR112022000394A2 (pt) Produção de fucosilactose em células hospedeiras
BR112017022224A2 (pt) processos integrados para produzir, e processo para preparar uma composição
BR112014002546A2 (pt) "colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7"
MX2022007571A (es) Metodo de produccion de promotor de crecimiento vegetal, promotor de crecimiento vegetal y metodo de promocion de crecimiento vegetal.
MX2023002221A (es) Sistema de baculovirus modificado para produccion mejorada de adn de extremo cerrado (adnce).
BR112019023881A2 (pt) otimização da expressão de serino proteases em células hospedeiras
AR116615A2 (es) Operaciones de cosecha mejoradas para proteínas recombinadas
CL2022001679A1 (es) Células de levadura y métodos para la producción de e8,e10-dodecadienil coenzima a, codlemona y derivados
WO2019098671A3 (ko) 재조합 미생물 및 이를 이용한 개미산 제조 방법
BR112015022189A2 (pt) microvesícula, método para produção e uso da mesma
CL2024002358A1 (es) Variante de fitasa; método de producción; composición; y su uso.
MX2021014456A (es) Generacion rapida y deterministica de microglia a partir de celulas madre pluripotentes humanas.
AR126966A2 (es) Una planta transgénica que presenta un rendimiento mejorado y tolerancia al estrés abiótico, y método de obtención de dicha planta
CL2023000566A1 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
MY208669A (en) L-methionine producing microorganism to which protein encoded by foreign metz gene is introduced and method for producing l-methionine using same
MX2022006748A (es) Composiciones de acidos nucleicos.
MX2022015802A (es) Construcciones de anellovirus en tandem.
MX2025010510A (es) Composiciones y metodos para la regulacion epigenetica de la expresion de pcsk9
PE20250795A1 (es) Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia
MX2022013253A (es) Proceso para la acilacion de un alfa, omega-alcanodiol.